Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fecal microbiota transplantation (FMT) oral capsules developed by Helsinki University Central Hospital are a microbial therapy designed to treat recurrent *Clostridioides difficile* infection (rCDI). The therapy involves the administration of processed healthy donor stool, encapsulated for oral delivery to restore a diverse and healthy gut microbiome. By reintroducing a complex community of beneficial bacteria, the treatment aims to restore colonization resistance and outcompete *C. difficile* populations. This specific formulation utilizes a production method established by Copenhagen University Hospital (Hvidovre Hospital) and has been evaluated in Phase 3 clinical trials to assess its efficacy and safety in adult patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fecal microbiota transplantation (Helsinki University Central Hospital).